C. Robert discusses PD-1 blockade in advanced melanoma, including CheckMate 067 and 069 studies where response rate and progression-free survival are better with a combination of anti-PD-1 and anti-CTLA4 blockade. As this combination leads to more toxicities, she speculates on the potential cases where it could be used.

Latest News